A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) therapy, a novel approach harnessing the power of a patient’s own immune system. In 2024, a first-of-its-kind drug was approved by the Food and Drug Administration (FDA) for patients whose cancer has progressed after other treatments.

In this issue of *CURE*, we highlight the details of this groundbreaking treatment, explaining how it differs from traditional immunotherapy and targeted therapies. You’ll learn about the steps involved, from tumor removal and T-cell manufacturing to the infusion process and the role of high-dose interleukin-2 in boosting the immune response, as well as crucial postinfusion care.

While TIL therapy presents a promising new avenue, it’s important for patients to understand both its potential benefits and its challenges. A key advantage is that it’s designed as a one-time treatment, potentially offering a lasting response without the need for continuous therapy. However, the treatment is rigorous, requires a substantial time commitment and is currently available only at a limited number of medical centers. Additionally, the cost of TIL therapy is significant, although financial assistance programs are being explored.

You’ll hear from experts who dive into this exciting advancement, as it offers a personalized and potentially impactful approach for patients who have limited options. Further, as research continues, this innovative strategy may hold promise for other cancers as well, expanding the arsenal of tools available in cancer care.

Also in this issue, we recognize our 2025 Extraordinary Healer® award winner, Kaifan Zhao, AGACNP-BC, PMHNP-BC, for his dedication to making a difference in the lives of patients and their loved ones. The event, held during the 50th Annual Oncology Nursing Society Congress, also featured a keynote lecture from journalist, podcaster and author Amy Robach. “You are walking with \[patients with cancer] during the scariest time of their lives,” she said. “They are afraid for their lives. They are afraid to think about tomorrow. They’re fighting for tomorrow, and you are there as their backbone, as their support, as their light,” she said.

If you are inspired by the testaments shared by our Extraordinary Healer finalists, essay nominations for the 2026 award ceremony are now open on curetoday.com. It is with your nominations that we can recognize the amazing feats of our oncology nursing community.

Staying informed is a powerful tool in your cancer journey. For the very latest updates in oncology, including breaking news on FDA approvals and expert perspectives on key cancer information, turn to curetoday.com.

We are dedicated to ensuring you have the information you need to navigate your cancer experience with clarity. Within these pages and on our website, you’ll find both personal narratives that resonate and expert opinions that provide context. We hope this information serves you well and offers encouragement. Thank you for your continued readership.

For more news on cancer updates, research and education,

don’t forget to subscribe to CURE®’s newsletters here.

Articles

Tumor-infiltrating lymphocyte (TIL) therapy represents a significant advancement in advanced melanoma treatment, utilizing a patient's immune system. The FDA approved a pioneering drug in 2024 for patients with treatment-resistant cancer. TIL therapy, distinct from traditional immunotherapy, involves tumor removal, T-cell manufacturing, and infusion, with high-dose interleukin-2 enhancing immune response. Despite its promise, TIL therapy is rigorous, costly, and limited in availability. The approach offers a personalized treatment option, with potential applications in other cancers. The issue also highlights the 2025 Extraordinary Healer® award and encourages essay nominations.

A significant development in the treatment of advanced melanoma has recently emerged: tumor-infiltrating lymphocyte (TIL) therapy.

CURE Summer 2025

A New Frontier in Melanoma Treatment

Latest News